2024-01-24 | Orviglance Review Article Published in Investigative Radiology PDF Report Presentation Webcast
2023-12-07 | Ascelia Pharma Announces Start of Image Reading Phase and Re-confirms Phase 3 SPARKLE Results by May 2024 PDF Report Presentation Webcast
Regulatory 2023-11-09 | Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program PDF Report Presentation Webcast
2023-10-04 | Ascelia Pharma Gets Acceptance for Publication of Orviglance Review Article in Investigative Radiology PDF Report Presentation Webcast
2023-09-13 | Ascelia Pharma to Reach Headline Results from SPARKLE Re-Evaluation by May 2024 with Current Funding PDF Report Presentation Webcast
2023-08-09 | Ascelia Pharma provides clarifications around the intra-reader variability in read-out of images in the SPARKLE study PDF Report Presentation Webcast
Regulatory 2023-08-07 | Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE PDF Report Presentation Webcast
Regulatory 2023-06-16 | Ascelia Pharma presented Orviglance Hepatic Impairment Data and hosted a Q&A with liver imaging experts at the 2023 ESGAR Annual Meeting PDF Report Presentation Webcast
2023-04-25 | Hepatic Impairment Study Accepted for Presentation at Major Radiology and Liver Conferences PDF Report Presentation Webcast
2023-03-14 | Welcome to Ascelia Pharma Investor Update: Bringing Orviglance to Market – Next Steps Towards Launch PDF PDF Report Presentation Webcast
2023-03-13 | Third US patent strengthens patent protection for Ascelia Pharma’s Oncoral (daily tablet irinotecan) PDF Report Presentation Webcast
2023-03-06 | INVITATION TO ASCELIA PHARMA INVESTOR UPDATE: BRINGING ORVIGLANCE TO MARKET – NEXT STEPS TOWARDS LAUNCH PDF Report Presentation Webcast
2023-03-03 | Ascelia Pharma achieves Last Patient Last Visit (LPLV) in the Orviglance Phase 3 SPARKLE Study which now includes 85 completed patients. PDF Report Presentation Webcast
2023-02-24 | Ascelia Pharma meets major milestone with patient enrollment completion for Orviglance Phase 3 Study, SPARKLE PDF Report Presentation Webcast
Regulatory 2023-02-21 | Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program PDF Report Presentation Webcast
Regulatory 2022-12-02 | Nomination Committee appointed for AGM 2023 in Ascelia Pharma AB PDF Report Presentation Webcast